These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 22075285)

  • 41. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome.
    Hinz M; Wree A; Jochum C; Bechmann LP; Saner F; Gerbes AL; Gerken G; Canbay A
    Ann Hepatol; 2013; 12(1):92-9. PubMed ID: 23293199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Terlipressin resolves ascites of cirrhotic rats through downregulation of aquaporin 2.
    Huang YY; Sun JY; Wang JY; Bai CX; He BM
    J Int Med Res; 2012; 40(5):1735-44. PubMed ID: 23206455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
    Alessandria C; Venon WD; Marzano A; Barletti C; Fadda M; Rizzetto M
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1363-8. PubMed ID: 12468959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Terlipressin in hepatorenal syndrome.
    Mazur JE; Cooper TB; Dasta JF
    Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
    Saner F; Kavuk I; Lang H; Biglarnia R; Frühauf NR; Schäfers RF; Malagó M; Broelsch CE
    Eur J Med Res; 2004 Feb; 9(2):78-82. PubMed ID: 15090293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Treatment of Hepatorenal Syndrome.
    Cavallin M; Fasolato S; Marenco S; Piano S; Tonon M; Angeli P
    Dig Dis; 2015; 33(4):548-54. PubMed ID: 26159272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study.
    Lata J; Marecek Z; Fejfar T; Zdenek P; Brůha R; Safka V; Hůlek P; Hejda V; Dolina J; Stehlík J; Tozzi I
    Hepatogastroenterology; 2007; 54(79):1930-3. PubMed ID: 18251131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
    Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
    United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
    Nguyen-Tat M; Götz E; Scholz-Kreisel P; Ahrens J; Sivanathan V; Schattenberg J; Rey JW; Wörns MA; Galle PR; Marquardt JU
    Dtsch Med Wochenschr; 2015 Jan; 140(2):e21-6. PubMed ID: 25612289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
    Ma AT; Solé C; Juanola A; Escudé L; Napoleone L; Avitabile E; Pérez-Guasch M; Carol M; Pompili E; Gratacós-Ginés J; Soria A; Rubio AB; Cervera M; Moreta MJ; Morales-Ruiz M; Solà E; Poch E; Fabrellas N; Graupera I; Pose E; Ginès P
    J Hepatol; 2024 Sep; 81(3):441-450. PubMed ID: 38479614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
    Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
    Salerno F; Cazzaniga M; Merli M; Spinzi G; Saibeni S; Salmi A; Fagiuoli S; Spadaccini A; Trotta E; Laffi G; Koch M; Riggio O; Boccia S; Felder M; Balzani S; Bruno S; Angeli P;
    J Hepatol; 2011 Dec; 55(6):1241-8. PubMed ID: 21703199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites.
    Yang YY; Lin HC; Lin MW; Chu CJ; Lee FY; Hou MC; Lee SD; Lee WP; Liu TT; Jap TS
    Clin Sci (Lond); 2011 Dec; 121(11):509-21. PubMed ID: 21692745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
    Halimi C; Bonnard P; Bernard B; Mathurin P; Mofredj A; di Martino V; Demontis R; Henry-Biabaud E; Fievet P; Opolon P; Poynard T; Cadranel JF
    Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
    Torre A; Terra C; Guevara M; Ginès P
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():8-14. PubMed ID: 15195529
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis.
    Salman TA; Edrees AM; El-Said HH; El-Abd OL; El-Azab GI
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):777-85. PubMed ID: 27097354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
    Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis.
    Fagundes C; Ginès P
    Am J Kidney Dis; 2012 Jun; 59(6):874-85. PubMed ID: 22480795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.